Using Triton WR-1339-induced hyperlipidaemic rats as an experimental model, we investigated whether compound 1 (N-(3-benzoylphenyl)-1H-indole-2-carboxamide) and 2 (N-(4-benzoylphenyl)-1H-indole-2-carboxamide) novel anti-hyperlipidaemic agents have any effect on plasma triglyceride, total cholesterol (TC) and high-density lipoprotein cholesterol levels (HDL-C) levels. Hyperlipidaemia was developed by intraperitoneal injection of Triton WR-1339 (200 mg/kg body weight). At a dose of 15 mg/kg body weight, compounds 1, 2 and bezafibrate (BF) significantly reduced the elevated plasma triglyceride levels after 7 and 24 h. Furthermore, HDL-C levels were remarkably increased in all treated groups after 7 and 24 h compared with the hyperlipidaemic control group. However, only compounds 1 and 2-treated groups clearly showed a significant reduction in plasma TC levels after 24 h. It is therefore reasonable to assume that compounds 1 and 2 may have a promising potential in the treatment of hyperlipidaemia and coronary heart diseases.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.